Predicting response to immunotherapy in lung cancer: an early HTA of predictive tests
International Journal of Technology Assessment in Health Care · 2025
DOI: 10.1017/s0266462325100317 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Technology Assessment in Health Care, 2025. Verfasst von Tim Govers und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Imaging, https://ror.org/05wg1m734Radboud University Medical Center, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Lung Neoplasms, Immunotherapy, Carcinoma, Non-Small-Cell Lung, Technology Assessment, Biomedical. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Predictive biomarkers can identify patients who are more likely to respond to immunotherapy, which can guide treatment decisions. The objective of this study was to assess the potential value of predictive biomarkers in advanced NSCLC patients to guide the development of cost-effective biomarkers in this field.
Methods
A decision analytical model was constructed to compare theoretical new strategies with biomarkers to the current standard of care. The analysis was performed for three different patient groups based on PD-L1 status. Differences in health outcomes (QALYs) and costs were assessed between the current practice and these biomarker strategies.
Results
Omitting immunotherapy in NSCLC patients with a PD-L1 score < 1 percent or between 1 and 49 percent, and a negative biomarker test, could potentially reduce healthcare costs significantly a small loss in QALYs. In these groups, a biomarker test is potentially cost-effective as the incremental cost-effectiveness ratio largely exceeds a willingness-to-accept threshold of €80,000 saved per QALY lost. For patients with a PD-L1 score > 50 percent, a considerable QALY gain can potentially be realized by adding chemotherapy to patients with a negative biomarker test. However, this comes at a significant increase in costs and appears not to be cost-effective.
Conclusions
In general, predictive biomarkers seem to have the potential to increase the cost-effectiveness of treatment with immunotherapy in patients with advanced NSCLC. Optimal positioning of a biomarker depends on the weighing between health impact and costs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Imaging, https://ror.org/05wg1m734Radboud University Medical Center, Nijmegen, The Netherlands.
- Medip Analytics, Nijmegen, The Netherlands.
- https://ror.org/03c9hf945Pamgene International, Den Bosch, The Netherlands.
- Department of Pulmonary Diseases, https://ror.org/05wg1m734Radboud University Medical Center, Nijmegen, The Netherlands.
ORCID-Profile: Tim Govers, Evelien van Well
Zitieren
APA
Govers, T., van Well, E., De Wijn, R., & van den Heuvel, M. (2025). Predicting response to immunotherapy in lung cancer: an early HTA of predictive tests. International Journal of Technology Assessment in Health Care. https://doi.org/10.1017/s0266462325100317
Vancouver
Govers T, van Well E, De Wijn R, van den Heuvel M. Predicting response to immunotherapy in lung cancer: an early HTA of predictive tests. International Journal of Technology Assessment in Health Care. 2025. doi:10.1017/s0266462325100317
BibTeX
@article{Govers2025,
author = {Govers, Tim and van Well, Evelien and De Wijn, Rik and van den Heuvel, Michel},
title = {Predicting response to immunotherapy in lung cancer: an early HTA of predictive tests},
journal = {International Journal of Technology Assessment in Health Care},
year = {2025},
doi = {10.1017/s0266462325100317}
}
EUVIMED